Press Releases Processa Pharmaceuticals, Inc.

Equities

PCSA

US74275C3043

Real-time Estimate Cboe BZX Other stock markets 12:06:23 2024-05-09 EDT			5-day change	1st Jan Change
2.22 ^USD	-10.48%		-3.98%	-67.57%

04-30	Processa Pharmaceuticals, Inc. Names Steven Cha as Senior Vice President of Clinical Research	CI
04-30	Certain Common Warrants of Processa Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-APR-2024.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference	05-06	AQ
Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research	04-30	AQ
Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial	04-11	AQ
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference	03-28	AQ
Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting	03-25	AQ
Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference	02-21	AQ
Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference	02-14	AQ
Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule	02-06	AQ
Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering	02-01	AQ
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI	01-30	AQ
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering	01-26	GL
Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses	01-25	AQ
Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer	01-19	AQ
Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split	01-18	AQ
Processa Pharmaceuticals to Present at the Biotech Showcase 2024	01-02	AQ
Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine	12-19	AQ
Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine	12-13	AQ
Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference	11-30	AQ
Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook	11-29	AQ
Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson	11-13	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Processa Pharmaceuticals, Inc.

Equities

PCSA

US74275C3043

Press Releases

Filters